Singapore markets close in 17 minutes

hVIVO plc (CRO.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.3320-0.0140 (-4.05%)
As of 08:15AM CEST. Market open.

hVIVO plc

21 Plumbers Row
London E1 1EQ
United Kingdom
44 20 7756 1300

Full-time employees274

Key executives

NameTitlePayExercisedYear born
Dr. Yamin Mohammed Khan Ph.D.CEO & Director702.48kN/A1969
Mr. Stephen PinkertonCFO & Executive Director220.08kN/A1963
Mr. Andrew CatchpoleChief Scientific OfficerN/AN/AN/A
Dr. Maurice N. Treacy Ph.D.Chief Commercial OfficerN/AN/AN/A
Ms. Teja Marathe-SarvadikarHead of QAN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing of vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, it offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

Corporate governance

hVIVO plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.